Stocktoria

Viridian Therapeutics, Inc.DE VRDN

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-18
Chart by TradingView
2/9
Piotroski F — financial health
2.72
Altman Z″ — distress risk · safe
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$70.8M$302,000$314,000$1.8M$3.0M
Operating income-$363.4M-$299.0M-$254.4M-$134.3M-$79.7M
Net income-$342.6M-$269.9M-$237.7M-$129.9M-$79.4M
Operating cash flow-$276.4M-$232.3M-$184.2M-$93.8M-$54.6M
Free cash flow-$276.9M-$232.8M-$185.1M-$94.6M-$54.9M
Total assets$899.4M$742.4M$490.4M$435.1M$203.7M
Total liabilities$177.3M$70.8M$48.4M$40.0M$16.0M
Shareholders' equity$722.2M$671.6M$442.0M$395.1M$187.7M
Ratios
Operating margin-512.9%-99018.2%-81035.0%-7579.2%-2690.8%
Net margin-483.6%-89387.1%-75711.5%-7329.2%-2680.2%
FCF margin-390.8%-77096.0%-58938.9%-5340.6%-1853.5%
Return on assets-38.1%-36.4%-48.5%-29.8%-39.0%
Return on equity-47.4%-40.2%-53.8%-32.9%-42.3%
Debt / equity0.03×0.05×0.01×0.00×
Current ratio12.6515.4318.2612.9314.68
Revenue growth23359.9%-3.8%-82.3%-40.2%182.2%

Notable holders (13F)

InvestorSharesValue
Point72 Asset Management, L.P.322,836$6.3M
RENAISSANCE TECHNOLOGIES LLC203,100$4.0M

Why these scores methodology →

Piotroski F-score: 2/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 2.72 (safe)

  • Working capital / assets 0.916
  • Retained earnings / assets -1.488
  • EBIT / assets -0.404
  • Equity / liabilities 4.074

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001590750 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.